Update on Transition of CRYSVITA® (burosumab-twza) Injection to Kyowa Kirin
Kyowa Kirin is a top 50 global pharmaceutical company headquartered in Japan. Around the world, our core values drive us to do everything we can to answer the needs of patients, their families, and medical professionals.
Our history of innovation is built on forming collaborations that accelerate the delivery of scientific advances to patients. After discovering CRYSVITA® (burosumab-twza) injection, Kyowa Kirin partnered with Ultragenyx Pharmaceutical Inc. to successfully develop and make it available to appropriate patients, with Ultragenyx responsible for North America, Latin America and Turkey, and Kyowa Kirin focused on Europe, Asia and Australia.
In 2023, we begin the next phase of our long-standing collaboration. Kyowa Kirin will assume primary commercial responsibility for CRYSVITA in the U.S. and Canada at the end of April while Ultragenyx continues to lead efforts in Latin America and Turkey.
As we continue to work together to ensure a smooth commercial transition, the patient experience remains our top priority.
CRYSVITA patient support program
Beginning May 1, 2023, support for CRYSVITA patients and caregivers will be provided through Kyowa Kirin Cares, including services related to insurance and access, financial assistance, and treatment education supported by a team of experienced case managers.
If you are currently enrolled in the Ultragenyx UltraCare® program, you must opt-in to Kyowa Kirin Cares to maintain your eligibility to receive support services following the transition, including financial assistance programs.
By the end of February 2023, UltraCare patients will receive more information describing the Kyowa Kirin Cares program and how to opt-in.
If you have questions or
need more information.